{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-325856","form_type":"8-K","ticker":"BMRN","cik":"0001048477","company_name":"BIOMARIN PHARMACEUTICAL INC","filed_at":"2025-12-19T23:59:59+00:00","discovered_at":"2026-05-14T18:02:38.654590+00:00","generated_at":"2026-05-16T12:31:00.874894+00:00","sec_items":["1.01","7.01","9.01"],"event_type":"m_and_a","sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"confidence":"high","headline":"BioMarin to acquire Amicus Therapeutics for $4.8B in all-cash deal at $14.50/share","bullets":["BioMarin acquires Amicus for $14.50/share in cash, total equity value ~$4.8B; expected Q2 2026 close.","Acquisition adds Galafold (Fabry) and Pombiliti+Opfolda (Pompe) products; Amicus's trailing 12-month revenue $599M.","BioMarin secures up to $3.65B bridge loan from Morgan Stanley to fund transaction.","Deal expected to be accretive to Non-GAAP diluted EPS in first 12 months post-close, substantially accretive from 2027.","Amicus board unanimously recommends; subject to Amicus stockholder approval and regulatory clearances."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-325856","json":"https://secwatch.observer/filing/0001193125-25-325856.json","markdown":"https://secwatch.observer/filing/0001193125-25-325856.md","text":"https://secwatch.observer/filing/0001193125-25-325856.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1048477/000119312525325856/0001193125-25-325856-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1048477/000119312525325856/d49247d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T12:31:00.874894+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}